NUDT16L1

Across TCGA pan-cancer cohorts, NUDT16L1 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of NUDT16L1’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where NUDT16L1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types NUDT16L1 is over-expressed in tumor, although a few such as KICH and KIRC show the opposite, repressed pattern.

LIHC, BRCA, and LUAD are the cancer types where NUDT16L1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in NUDT16L1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	All	+0.960	<.001	9	view →
BRCA	All	III,IV	+1.068	<.001	6	view →
LUAD	Female	All	+0.478	<.001	5	view →
KICH	All	All	−0.628	.001	4	view →
CHOL	All	All	+0.593	.005	4	view →
COAD	Female	All	+0.493	.003	4	view →
KIRC	Male	All	−0.361	.001	4	view →
STAD	All	II,III,IV	+0.499	.003	3	view →
HNSC	Male	III,IV	+0.436	.002	3	view →
UCEC	All	All	+0.373	.047	2	view →
THCA	All	IV	−0.307	.011	2	view →
THCA	All	All	+0.257	.002	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

NUDT16L1–LIHC

Open the LIHC breakdown →